{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:12Z","timestamp":1791903312449,"version":"4.3.4"},"reference-count":20,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"DOI":"10.1182\/bloodadvances.2026020073","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:02:16Z","timestamp":1781301736000},"page":"6641-6644","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Bispecific antibodies are becoming the preferred standard of care in relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-8007","authenticated-orcid":false,"given":"Murali","family":"Janakiram","sequence":"first","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"8","key":"2026101310421575900_bib1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"issue":"2","key":"2026101310421575900_bib2","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"suppl 1","key":"2026101310421575900_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2025-133","article-title":"Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: a CIBMTR analysis","volume":"146","author":"Mian","year":"2025","journal-title":"Blood"},{"key":"2026101310421575900_bib4","unstructured":"Johnson & Johnson\n          . TECVAYLI Monotherapy Demonstrates Superior Progression-Free and Overall Survival Versus Standard of Care As Early As First Relapse In Patients With Multiple Myeloma Predominantly Refractory to Anti-CD38 Therapy and Lenalidomide. Accessed 18 January 2026. https:\/\/www.jnj.com\/media-center\/press-releases\/tecvayli-monotherapy-demonstrates-superior-progression-free-and-overall-survival-versus-standard-of-care-as-early-as-first-relapse-in-patients-with-multiple-myeloma-predominantly-refractory-to-anti-cd38-therapy-and-lenalidomide."},{"issue":"19","key":"2026101310421575900_bib20","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1182\/bloodadvances.2026019898","article-title":"CAR-T therapy is the preferred option in relapsed\/refractory multiple myeloma","volume":"10","author":"Banerjee","year":"2026","journal-title":"Blood Adv"},{"issue":"2","key":"2026101310421575900_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026101310421575900_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2026101310421575900_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.clml.2025.05.015","article-title":"Retreatment with anti-CD38-based combinations in multiple myeloma in real-life: results from the Emmy cohort study","volume":"25","author":"Talbot","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2026101310421575900_bib8","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026101310421575900_bib9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026101310421575900_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026101310421575900_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026101310421575900_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101310421575900_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-024-01129-0","article-title":"Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel","volume":"14","author":"Banerjee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026101310421575900_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026101310421575900_bib15","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"issue":"18","key":"2026101310421575900_bib16","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026101310421575900_bib17","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1182\/blood-2025-5814","article-title":"Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed\/refractory multiple myeloma","volume":"146","author":"Razzo","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026101310421575900_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"2026101310421575900_bib19","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6641\/2592410\/blooda_adv-2026-020073-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6641\/2592410\/blooda_adv-2026-020073-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:42:24Z","timestamp":1791902544000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6641\/569119\/Bispecific-antibodies-are-becoming-the-preferred"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":20,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020073","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,29]]}}}